P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

Hemasphere · 2022 · PMC9430057

Europe PMC

hedged sentence

0.0320

closest p · 0.6× alpha

0.0320

boldest claim

The sentences

showed a trendp=0.032actually significant

Analysis of a subset of pts with cytogenetic data showed a trend towards lower baseline sBCMA levels in the standard-risk group (n=18) vs the high-risk group (n=42; p=0.032).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.